Catalog No.
DHB86914
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
Research Grade Biosimilar
Target
HER1, Receptor tyrosine-protein kinase erbB-1, Proto-oncogene c-ErbB-1, Epidermal growth factor receptor, EGFR, ERBB1, ERBB
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P00533
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
Theraloc, hR3, CAS: 828933-51-3
Note
For research use only. Not suitable for clinical or therapeutic use.
Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck, PMID: 32537431
Nimotuzumab: beyond the EGFR signaling cascade inhibition, PMID: 30318080
Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study, PMID: 30830679
Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma, PMID: 32426197
177Lu-nimotuzumab, PMID: 22817873
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer, PMID: 31150120
Nimotuzumab Site-Specifically Labeled with 89 Zr and 225 Ac Using SpyTag/SpyCatcher for PET Imaging and Alpha Particle Radioimmunotherapy of Epidermal Growth Factor Receptor Positive Cancers, PMID: 33233524
90Y-DOTA-nimotuzumab: Synthesis of a Promising β⁻ radiopharmaceutical, PMID: 33397277
Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis, PMID: 30907986
Nimotuzumab, an EGFR‑targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma, PMID: 32319582
Nimotuzumab in pediatric glioma, PMID: 19903064
Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer, PMID: 32064043
Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft, PMID: 30800216
Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study, PMID: 31888551
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin, PMID: 20046573
89 Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I, PMID: 29682209
Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China, PMID: 32494195
Profile of nimotuzumab in the treatment of high-grade glioma, PMID: 25926743
Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma, PMID: 33008416
Nimotuzumab treatment of malignant gliomas, PMID: 23043252
Preclinical Evaluation of 111 In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models, PMID: 30655327
Time profile of nimotuzumab for enhancing radiosensitivity of the Eca109 cell line, PMID: 30854050
Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease, PMID: 30633365
Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature, PMID: 30417211
Nimotuzumab with intensity-modulated radiation therapy in unresectable and platinum-ineligible locally advanced head-and-neck cancer, PMID: 31956621
A radiopharmaceutical [ 89 Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo, PMID: 30826708
Anti-EGFR therapies in nasopharyngeal carcinoma, PMID: 32836074
Nimotuzumab for pediatric diffuse intrinsic pontine gliomas, PMID: 21171927
Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of 177 Lu-Nimotuzumab, PMID: 32657634
EGFR-targeted therapies in the post-genomic era, PMID: 28866730
Nimotuzumab Combined With Irradiation Enhances the Inhibition to the HPV16 E6-Promoted Growth of Cervical Squamous Cell Carcinoma, PMID: 32850421
Nimotuzumab Dosing and Outcomes in Locally Advanced Head and Neck Cancer, PMID: 31353134
Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer, PMID: 31564975
Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma, PMID: 32973932
Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro, PMID: 29552167
Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer, PMID: 28210119
Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity, PMID: 19624281
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas], PMID: 21575527
Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients, PMID: 28674498
Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [ 111 In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR, PMID: 31706737
Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma, PMID: 29920955
Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study, PMID: 31069191
[Nimotuzumab significantly enhances chemosensitivity of PC9 human lung adenocarcinoma cells to paclitaxel in vitro], PMID: 25676404
Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients, PMID: 24613543
Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3, PMID: 23232108
Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: A pilot study, PMID: 30235761
Nimotuzumab Inhibits Cholangiocarcinoma Cell Metastasis via Suppression of the Epithelial-Mesenchymal Transition Process, PMID: 28668850
Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab, PMID: 18097777
Nimotuzumab plus chemotherapy with docetaxel, cisplatin, 5-fluorouracil for locally advanced head and neck squamous cell carcinoma: A clinical study, PMID: 30964103
Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study, PMID: 29285832
For research use only. Not for human or drug use.
